TY - JOUR AU - Rogister, Bernard PY - 2017 TI - The CXCL12/CXCR4 pathway or the autocrine proliferative loop of the glioblastoma stem cells JF - Translational Cancer Research; Vol 6, Supplement 2 (March 31, 2017): Translational Cancer Research Y2 - 2017 KW - N2 - Despite multimodal therapy (the classical Stupp’s protocol) including surgical resection (as large as possible), radiotherapy and chemotherapy, glioblastoma (GBM) remain a burden as the global survival rate at two years reaches barely 9% of patients (1). This situation is mainly a consequence of a systematic recurrence and this recurrence is itself a consequence of various causes, acting alone or synergistically: heterogeneous nature of the disease (2), the presence of the brain-blood barrier which impedes the potentially active drugs to get into the brain (3), the lack of targeted chemotherapeutic molecules and the persistence of GBM-initiating or stem cells (GSC) (4). UR - https://tcr.amegroups.org/article/view/12676